O
Olga Tanaseichuk
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 8
Citations - 6758
Olga Tanaseichuk is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Drug resistance & Genome. The author has an hindex of 5, co-authored 8 publications receiving 2855 citations.
Papers
More filters
Journal ArticleDOI
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.
Yingyao Zhou,Bin Zhou,Lars Pache,Max W. Chang,Alireza Hadj Khodabakhshi,Olga Tanaseichuk,Christopher Benner,Sumit K. Chanda +7 more
TL;DR: A biologist-oriented portal that provides a gene list annotation, enrichment and interactome resource and enables integrated analysis of multi-OMICs datasets, Metascape is an effective and efficient tool for experimental biologists to comprehensively analyze and interpret OMICs-based studies in the big data era.
Journal ArticleDOI
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
Annie N. Cowell,Eva S. Istvan,Amanda K. Lukens,Amanda K. Lukens,Maria G. Gomez-Lorenzo,Manu Vanaerschot,Tomoyo Sakata-Kato,Erika L. Flannery,Pamela Magistrado,Edward Owen,Matthew Abraham,Gregory LaMonte,Heather J. Painter,Roy Williams,Virginia Franco,María Linares,Ignacio Arriaga,Selina Bopp,Victoria C. Corey,Nina F. Gnädig,Olivia Coburn-Flynn,Christin Reimer,Purva Gupta,James M. Murithi,Pedro A. Moura,Olivia Fuchs,Erika Sasaki,Sang W. Kim,Christine H. Teng,Lawrence T. Wang,Aslı Akidil,Sophie H. Adjalley,Paul Willis,Dionicio Siegel,Olga Tanaseichuk,Yang Zhong,Yingyao Zhou,Manuel Llinás,Sabine Ottilie,Francisco-Javier Gamo,Marcus C. S. Lee,Marcus C. S. Lee,Daniel E. Goldberg,David A. Fidock,Dyann F. Wirth,Dyann F. Wirth,Elizabeth A. Winzeler,Elizabeth A. Winzeler +47 more
TL;DR: Genome sequencing elucidates potential drug resistance in the malaria parasite and identifies antimalarial targets and drug-resistance genes, as well as discovering hitherto unrecognized drug target–inhibitor pairs.
Journal ArticleDOI
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission
David Plouffe,Melanie Wree,Alan Y. Du,Stephan Meister,Fengwu Li,Kailash P. Patra,Aristea Lubar,Shinji L. Okitsu,Erika L. Flannery,Nobutaka Kato,Olga Tanaseichuk,Eamon Comer,Bin Zhou,Kelli Kuhen,Yingyao Zhou,Didier Leroy,Stuart L. Schreiber,Stuart L. Schreiber,Christina Scherer,Joseph M. Vinetz,Elizabeth A. Winzeler +20 more
TL;DR: SaLSSA analysis of 13,983 unique compounds uncovered that >90% of well-characterized antimalarials, including endoperoxides and 4-aminoquinolines, as well as compounds active against asexual blood stages, lost most of their killing activity when parasites developed into metabolically quiescent stage V gametocytes.
Journal ArticleDOI
A broad analysis of resistance development in the malaria parasite
Victoria C. Corey,Amanda K. Lukens,Amanda K. Lukens,Eva S. Istvan,Marcus C. S. Lee,Virginia Franco,Pamela Magistrado,Olivia Coburn-Flynn,Tomoyo Sakata-Kato,Olivia Fuchs,Nina F. Gnädig,Greg Goldgof,María Linares,Maria G. Gomez-Lorenzo,Cristina de Cozar,Maria Jose Lafuente-Monasterio,Sara Prats,Stephan Meister,Olga Tanaseichuk,Melanie Wree,Yingyao Zhou,Paul Willis,Francisco-Javier Gamo,Daniel E. Goldberg,David A. Fidock,Dyann F. Wirth,Dyann F. Wirth,Elizabeth A. Winzeler +27 more
TL;DR: The data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing on fast-killing compounds may result in a slower onset of clinical resistance.
Posted ContentDOI
Mapping The Malaria Parasite Drug-Able Genome Using In Vitro Evolution And Chemogenomics
Annie N. Cowell,Eva S. Istvan,Amanda K. Lukens,Maria G. Gomez-Lorenzo,Manu Vanaerschot,Tomoyo Sakata-Kato,Erika L. Flannery,Pamela Magistrado,Matthew Abraham,Gregory LaMonte,Roy Williams,Virginia Franco,Ignacio Arriago,María Linares,Selina Bopp,Victoria C. Corey,Nina F. Gnädig,Olivia Coburn-Flynn,Christin Reimer,Purva Gupta,James M. Murithi,Olivia Fuchs,Erika Sasaki,Sang W. Kim,Christine H. Teng,Lawrence T. Wang,Paul Willis,Dionicio Siegel,Olga Tanaseichuk,Yang Zhong,Yingyao Zhou,Sabine Otillie,Francisco-Javier Gamo,Marcus C. S. Lee,Daniel E. Goldberg,David A. Fidock,Dyann F. Wirth,Elizabeth A. Winzeler +37 more
TL;DR: This comprehensive genome analysis of 262 Plasmodium falciparum parasites treated with 37 diverse compounds reveals how the parasite evolves to evade the action of small molecule growth inhibitors and identifies new antimalarial drug targets.